Should I buy Abbott Laboratories (ABT)?

What Strong Buy means for ABT today

A Strong Buy rating is the output of the composite fair-value band ($87.2–$127) compared with the live price ($84.3), a 9/10 moat score, and a 88/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

ABT is rated Strong Buy at $84.32 versus the reconciled fair value midpoint of $107.02, implying +26.92% upside/downside. Confidence is separately disclosed at 88/100. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 20%): target $127.26, return +50.9%. Base case (probability 60%): target $107.02, return +26.9%. Bear case (probability 20%): target $87.24, return +3.5%.

Probability weights are not symmetric. Abbott Laboratories is a mature-dividend stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for Abbott Laboratories are: Libre Market Share Loss; Nutrition Margin Collapse; Dividend Sustainability Crisis. The single biggest risk is Libre Market Share Loss: Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.

The biggest opportunity is Bull: Innovation in Medical Devices and sustained recovery in routine Diagnostics outpace expectations, yielding significant operating leverage. FCF conversion accelerates, enabling aggressive dividend hikes and synergistic acquisitions without compromising the balance sheet. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Strong Buy rating with 88/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/abt/analysis.

Frequently asked questions